VACH
Voyager Acquisition Corp.10.57
+0.00+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
334.28MP/E (TTM)
35.23Basic EPS (TTM)
0.30Dividend Yield
0%Recent Filings
10-Q
8-K
SPAC deal extended
Voyager Acquisition Corp. amended its April 2025 business combination agreement with Veraxa Biotech AG on October 18, 2025, extending the end date to August 7, 2026, while scrapping the SPAC termination fee for certain endings. This buys time for the deal amid regulatory hurdles. Risks loom large. Forward-looking statements abound.
8-K
SPAC-Veraxa biotech merger announced
Voyager Acquisition Corp. unveiled an investor presentation on September 5, 2025, detailing its proposed business combination with Veraxa Biotech AG, a Swiss oncology innovator developing BiTAC platforms for safer cancer therapies targeting solid tumors. The deal implies a pro forma enterprise value of $1.3 billion, funded by $253 million from Voyager's trust and a $25 million PIPE, with existing Veraxa shareholders rolling over 100% of their equity and closure eyed for Q4 2025. Yet regulatory approvals and redemptions loom large. BiTAC advances precision.
10-Q
Q2 FY2025 results
Voyager Acquisition Corp. swung to a $2.5M net income for Q2 ended June 30, 2025, up from a $50,808 loss a year earlier, fueled by $2.7M in Trust Account investment income that offset $241K in administrative costs—yet operating losses held steady at $241K. For the half-year, net income hit $4.9M versus last year's $103K loss, with Trust assets climbing 2.1% q/q to $264.5M on interest accretion, while cash outside dipped to $92K amid $576K operating outflows. EPS aligned neatly at $0.08 for redeemable Class A shares on 25.3M weighted average, confirming no dilution quirks. Liquidity stays solid with sponsor backstops, but the April 2025 Veraxa Biotech merger deal—merging Voyager into a Swiss PubCo—carries execution risks from regulatory scrutiny. No debt burdens; non-GAAP metrics not disclosed in the 10-Q. Sponsor waivers preserve runway, though geopolitical tensions could snag the combo.
8-K
Joinder advances biotech SPAC merger
Voyager Acquisition Corp. signed a Joinder Agreement on July 16, 2025, binding Veraxa Biotech Holding AG and Veraxa Cayman Merger Sub to the April 22, 2025 Business Combination Agreement with Veraxa Biotech AG. This move outlines asset transfers from Voyager to Merger Sub and share contributions to the holding company, advancing the SPAC merger. Risks include regulatory delays and shareholder redemptions. Deal structure tightens.
BAYA
Bayview Acquisition Corp
11.63-0.01
HYAC
Haymaker Acquisition Corp. 4
11.34+0.04
LOKV
Live Oak Acquisition Corp. V
10.27+0.02
MCAG
Mountain Crest Acquisition Corp
12.29+0.00
PACH
Pioneer Acquisition I Corp
10.11+0.01
SVCC
Stellar V Capital Corp.
10.38+0.00
TACH
Titan Acquisition Corp.
10.24-0.01
TDAC
Translational Development Acqui
10.42+0.00
YHNA
YHN Acquisition I Limited
10.65+0.00
YOTA
Yotta Acquisition Corporation
2.00+0.00